Innovative Drug That Promotes Bone Regrowth To Be Launched In A Couple of Weeks

Romosozumab, which is also known as Evenity, gained approval from European countries recently and is being touted as the first major breakthrough in bone thinning treatment. The condition is associated with fractures in around one in three women who are over 50 years old.

Treatment data will be scrutinized by the National Institute for Health and Care Excellence, an organization that is expected to support the approval of the drugs for osteoporosis patients. The drug is designed for those who are deemed at higher risk of suffering from fractures.

There are already existing treatments designed to slow down bone loss. This new drug and treatment method, however, goes beyond that. Using monthly injections that will run for one year, the drug is expected to block the effects of sclerostin, a naturally occurring protein.

Various tests show the new drug reduces bone breakdown and increases the formation of new bone tissues. In one key test involving over 11,000 women suffering from postmenopausal osteoporosis, those on treatment saw their risk of experiencing spine fracture reduced to 73% compared to those on placebo.

Other tests have also proven that Evenity can lower the risk of other bone fractures, such as spine and hip fractures, compared to standard treatment methods. These tests have also proven patients continue to reap the drug’s benefits even when replaced by standard therapy after a year of administration.

Professor David Reid expressed his earnest desire to get his hands on this new drug for patients who will benefit from its positive effects. Reid also said that he believes the new drug will have a significant advantage over regular osteoporosis drugs. This is because it can increase bone density both in the hip and spine in a rather short period. Professor Reid is a leading expert on osteoporosis and a senior medical adviser to the Royal Osteoporosis Society Born Research Academy.

According to its makers, private patients may likely obtain this new drug beginning in March of this year. Many people in the UK eagerly wait for the release of the drug, considering that almost 3.5 million people in the country are suffering from this debilitating ailment.

A spokesperson from the National Institute for Health and Care Excellence or NICE has confirmed that the effects of the new drug will be evaluated during an appraisal meeting in April. NICE provides advice to the National Health Service in England and Wales on what drugs to procure or use.